Proteinuria
📧 Sign up to get email alerts when something new happens for Proteinuria.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-03-09Clinical Trial Update: The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria [Phase 4]
This clinical trial update reports on changes in urinary angiotensinogen excretion after valsartan treatment in patients with persistent pro…
-
CLINICAL_TRIALS trial_result · 2008-07-25Clinical Trial Update: Endothelin Receptor Antagonism in Proteinuric Nephropathy [Phase 1]
A Phase 1 clinical trial from the University of Edinburgh evaluating endothelin receptor antagonism for proteinuric nephropathy has complete…
-
CLINICAL_TRIALS trial_result · 2008-05-19Clinical Trial Update: Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria [NA]
This clinical trial evaluated Mucomyst (N-acetylcysteine) to reduce oxidative stress in diabetics with proteinuria; the study is completed.
-
CLINICAL_TRIALS trial_result · 2007-12-19Clinical Trial Update: High Doses of Candesartan Cilexetil on the Reduction of Proteinuria [Phase 3]
Phase 3 trial evaluating high doses of candesartan cilexetil for reducing proteinuria has completed; the snippet does not report trial resul…
-
CLINICAL_TRIALS trial_result · 2007-12-13Clinical Trial Update: Optimalization of Nephroprotection Using N-Acetylcysteine [NA]
Clinical trial evaluating optimization of nephroprotection with N-Acetylcysteine in patients with chronic kidney disease and proteinuria. Th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2007-09-12Clinical Trial Update: Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System [NA]
A completed clinical trial evaluating optimization of nephroprotection with renin-angiotensin-aldosterone system inhibitors in chronic kidne…
-
CLINICAL_TRIALS trial_result · 2006-10-09Clinical Trial Update: Olmesartan Medoxomil and Diabetic Nephropathy [Phase 3]
A Phase 3 trial evaluating Olmesartan Medoxomil for diabetic nephropathy in type 2 diabetes has been completed.